Viatris (VTRS) Short-Term Debt issuances (2020 - 2025)
Viatris' (VTRS) quarterly Short-Term Debt issuances came in at -$1.5 million in Q4 2025, little changed year-on-year from -$1.5 million in Q4 2024, and down 600.0% quarter-over-quarter from $300000.0 in Q3 2025.
Viatris (VTRS) Short-Term Debt issuances (2020 - 2025) Analysis & Trends
Viatris' Short-Term Debt issuances history runs 6 years deep, the most recent figure standing at -$1.5 million for Q4 2025.
- On a quarterly basis, Short-Term Debt issuances changed 0.0% year-over-year to -$1.5 million in Q4 2025; TTM through Mar 2026 was -$1.2 million, a 185.71% decrease from a year earlier, with the FY2025 full-year figure at $200000.0, changed N/A from the prior year.
- Short-Term Debt issuances fell to -$1.5 million in Q4 2025 per VTRS's latest filing, from $300000.0 in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $1.3 billion in Q2 2021 and bottomed at -$1.1 billion in Q1 2021.
- The 5-year median for Short-Term Debt issuances is -$1.5 million (2024), against an average of -$64.7 million.
- Across the five-year window, Short-Term Debt issuances jumped 124.42% in 2023 and plunged 1600.0% in 2024, its largest moves.
- Year by year, Short-Term Debt issuances stood at -$214.0 million in 2021, then sank by 133.83% to -$500.4 million in 2022, then soared by 100.02% to $100000.0 in 2023, then plunged by 1600.0% to -$1.5 million in 2024, then changed by 0.0% to -$1.5 million in 2025.
- Per Business Quant, the three latest VTRS Short-Term Debt issuances figures stand at -$1.5 million (Q4 2025), $300000.0 (Q3 2025), and $1.4 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.50 Mn |
| Dec 31, 2025 | -1.50 Mn |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | -1.50 Mn |
| Dec 31, 2024 | -1.50 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Dec 31, 2023 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | -22.90 Mn |
| Sep 30, 2023 | -22.90 Mn |
| Jun 30, 2023 | -181.50 Mn |
| Jun 30, 2023 | -181.50 Mn |
| Mar 31, 2023 | 204.60 Mn |
| Mar 31, 2023 | 204.60 Mn |
| Dec 31, 2022 | -500.40 Mn |
| Dec 31, 2022 | -500.40 Mn |